Patient receptiveness to statin therapy is higher when presented with lifetime risk rather than 10-year risk of cardiovascular disease: insights from the PALM registry
Reclassification of the Intermediate group classified according to HEARTSCORE taking in consideration individual genetic predisposition to Coronary artery disease.